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Introduction {#jon12642-sec-0050}
============

Frontotemporal lobar degeneration is a neurodegenerative disorder with heterogeneous clinical features, characterized by behavioral and language disorders, impaired social and executive dysfunction, and some patients also develop features of motor neuron disease, progressive supranuclear palsy, and cortical basal syndrome. It is highly heritable with an autosomal dominant family history in about 30‐50% FTLD patients,[1](#jon12642-bib-0001){ref-type="ref"} usually associated with mutations of microtubule‐associated protein tau (*MAPT*) gene.[2](#jon12642-bib-0002){ref-type="ref"} Families with *MAPT* mutations provide an opportunity to identify biomarkers for early neurodegenerative changes and tracking disease progression starting from asymptomatic stage.

Proton magnetic resonance spectroscopy (^1^H MRS) provides quantitative in vivo assessment of several brain metabolites in a single scan that are associated with early neurodegenerative pathology. ^1^H MRS measurements from the posterior cingulate gyrus have identified neurochemical abnormalities in both asymptomatic and symptomatic carriers of *MAPT* mutation.[3](#jon12642-bib-0003){ref-type="ref"} A decrease in the neuronal integrity marker N‐acetylaspartate (NAA) or NAA to creatine (NAA/Cr) and elevation in possible glial marker myoinositol (mI) or mI to creatine (mI/Cr) have been found in symptomatic patients with FTLD,[4](#jon12642-bib-0004){ref-type="ref"} while only elevation in mI/Cr has been found in asymptomatic *MAPT* mutation carriers in the posterior cingulate gyrus.[3](#jon12642-bib-0003){ref-type="ref"}

Longitudinal ^1^H MRS studies in Alzheimer\'s disease demonstrated longitudinal decline in the neuronal integrity marker NAA and elevation in mI,[5](#jon12642-bib-0005){ref-type="ref"}, [6](#jon12642-bib-0006){ref-type="ref"}, [7](#jon12642-bib-0007){ref-type="ref"} suggesting serial MRS is a potential biomarker for following the progression of neurodegenerative diseases. Establishing the trajectory of biomarker changes preceding the clinical disease onset during the asymptomatic stage in *MAPT* mutation carriers is crucial for assessing the effects of potential therapies that are currently being developed.

The objectives of this study were: (1) to longitudinally investigate the trajectory of change in ^1^H MRS measurements in *MAPT* mutations carriers who converted from asymptomatic to symptomatic status; and (2) to determine the time at which the neurochemical changes accelerated during disease progression.

Methods {#jon12642-sec-0060}
=======

Participants {#jon12642-sec-0070}
------------

Participants in this study were recruited from the Mayo Clinic Alzheimer\'s Disease Research Center (ADRC) and the Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) studies at the Mayo Clinic site between August 2006 to July 2017. LEFFTDS is a multisite study investigating the biomarkers of disease progression in familial FTLD mutation carriers. The current study included participants who screened positive for a mutation in *MAPT* with no clinical symptoms at baseline, but transitioned from asymptomatic to symptomatic disease during follow‐up, which we refer to as converters (*n* = 8; 4 females; median age = 41.5). Converters were from four individual families with *MAPT* mutations (four with N279K, two with V337M, one with P301L, and one with IVS9‐10G\>T mutations) with a mean score 29.75 (range 29‐30) on the Mini‐Mental State Examination (MMSE) at the baseline evaluation. All participants were followed prospectively with annual clinical examination at the time of MRI/^1^H MRS examination, including a medical history review, mental status examination, a neurological examination by a clinician with FTLD expertise and a neuropsychological examination.

None of the participants had structural lesions that could cause cognitive impairment or dementia, such as cortical infarction, subdural hematoma, or tumor, or had concurrent illness that would interfere with cognitive function other than FTLD on baseline and follow‐up examinations.

All participants have undergone genetic testing for research and the behavioral neurologists evaluating the participants were blinded to the findings of the genetic testing for research before the phenoconversion. Informed consent was obtained from all participants for participation in the studies, which were approved by the Mayo Institutional Review Board.

MRS and MRI {#jon12642-sec-0080}
-----------

Single voxel (SV) ^1^H MRS studies were performed at 3T using an eight‐channel phased array head coil (GE Healthcare, Milwaukee, WI). A 3‐dimensional high‐resolution T1‐weighted magnetization‐prepared rapid gradient echo (MPRAGE) acquisition with repetition time/echo time/inversion time = 7/3/900 milliseconds, flip angle 8 degrees, in‐plane resolution of 1.0 mm, and a slice thickness of 1.2 mm was performed in sagittal plane for voxel positioning. ^1^H MRS studies were performed using the automated MRS package (PROBE/SV; GE Healthcare). Point resolved spectroscopy sequence with repetition time = 2,000 milliseconds, echo time = 30 milliseconds, 2,048 data points, and 128 excitation was used for the examination.

An 8 cm^3^ (2 × 2 × 2 cm) voxel was placed by trained MRI technologists on a mid‐sagittal T1 weighted image, included right and left posterior cingulate gyri and inferior precunei. The anterior border of splenium, the superior border of corpus callosum and the cingulate sulcus were the anatomical landmarks to define the anterior inferior and the anterior superior border of the voxel. Individual voxel placements were visually evaluated by a trained image analyst for quality control. ^1^H MR spectra from voxels that were not properly placed according to predetermined anatomic landmarks, those with low signal‐to‐noise ratio (SNR), poor water suppression, lipid contamination, wide line widths or baseline distortions failed the quality control and were excluded. In this study, none of the spectra had to be excluded due to poor quality.

The PROBE\'s prescan algorithm automatically adjusts the transmitter and receiver gains and center frequency. The local magnetic field homogeneity is optimized with the 3‐plane auto‐shim procedure and the flip angle of the third water suppression pulse is adjusted for chemical shift water suppression (CHESS) prior to point‐resolved spectroscopy acquisition. Metabolite intensity ratios are automatically calculated using a previously validated algorithm at the end of each PROBE/SV.[8](#jon12642-bib-0008){ref-type="ref"}, [9](#jon12642-bib-0009){ref-type="ref"} ^1^H MRS metabolite ratios that were analyzed for this study included N‐acetylaspartate/Creatine (NAA/Cr), myo‐inositol (mI)/Cr, and NAA/mI based on previous cross‐sectional studies in *MAPT* mutation carriers showing abnormalities in these metabolite ratios.[3](#jon12642-bib-0003){ref-type="ref"}

Genetic Analysis {#jon12642-sec-0090}
----------------

Analysis of *MAPT* exons 1, 7, and 9‐13 was performed using primers and conditions that were previously published.[10](#jon12642-bib-0010){ref-type="ref"} PCR amplicons were purified using the Multiscreen system (Millipore, Billerica, MA) and then sequenced in both directions using Big Dye chemistry following the manufacturer\'s protocol (Applied Biosystems, Froster City, CA). Sequence products were purified using the Montage system (Millipore) before being run on an Applied Biosystem 3730 DNA Analyzer. Sequence data were analyzed using either SeqScape (Applied Biosystem) or Sequencher software (Gene Codes, Ann Arbor, MI).

Statistical Analysis {#jon12642-sec-0100}
--------------------

Baseline characteristics of converters with *MAPT* mutations were described with means, standard deviations, counts and proportions. We modeled the annual percent change of NAA/Cr, NAA/mI, and mI/Cr ratios using linear mixed effects models with a flex point in the fixed effects. The flex point models allow the regression slopes to change at some time before, at, or after the time of conversion. The models thus have two estimated regression lines, one with the first slope in the early times and one with the second slope at later times, with their point of intersection being the flex point. This flex point was estimated in the models using a dummy variable to shift the estimated line with the second slope up or down, thereby moving the flex point left or right. The specific coding in our models estimated a slope over the entire time, and then a modifier to the slope after the flex point. If the flex point was not significantly different from the time of conversion, we reduced to a more parsimonious model with slope change at the time of conversion. If in addition the slopes before and after the flex point did not differ, we reduced to a model with a single slope over the time span. We used *P* values, Akaike Information Criterion (AIC), and Bayesian Information Criterion (BIC) to evaluate the models. The mixed models used random intercepts to account for within‐subject repeated measures correlations nested in within‐family correlations. This allowed for dependence in the repeated measures per subject, and also dependence in family members. Families were assumed to be independent from each other. Because of the sample size restrictions, we were only able to use random intercepts in these models. Inclusion of random slopes and flex points would result in gross overfitting of the models, and nonconvergence.

Results {#jon12642-sec-0110}
=======

Table [1](#jon12642-tbl-0001){ref-type="table"} describes the baseline characteristics of the converters. The converters were followed for a median of 8.2 years (range 3.8 to 10.7 years) and had at least two ^1^H MRS scans from the posterior cingulate gyrus, with a total of 60 ^1^H MRS examinations included in eight participants. ^1^H MRS acquisitions from the posterior cingulate voxel past the quality control assessment and were successful for the quantification of metabolite ratios in all participants.

###### 

Participant Characteristics at Baseline

                               MAPT Mutation Carriers
  --------------------------- ------------------------
  Female, number (%)                 4 (50.0%)
  Education, year                      15 (1)
  Age at MRI scan, year                41 (6)
  MMSE                                30 (.46)
  NPI total                            1 (1)
  DRS total MOANS                      12 (2)
  AVLT delay recalled MOANS            12 (3)
  NAA/Cr ratio                       1.67 (.06)
  mI/Cr ratio                        0.54 (.04)
  NAA/mI ratio                       3.11 (.3)

Data shown are number (%) or mean (standard deviation).

MRI = magnetic resonance image; MMSE = Mini‐Mental State Examinations; NPI = Neuropsychiatric Inventory; DRS = Dementia rating scale; MOANS = Mayo\'s Older Americans Normative Studies; AVLT = Auditory‐verbal learning test; NAA = N‐acetylaspartate; Cr = creatine; mI = myoinositol.

John Wiley & Sons, Ltd.

The median age of symptom onset was 45.5 years with a range of 36‐58 years. At the time of conversion, all participants were classified as mild cognitive impairment (MCI), with two later developing behavioral variant frontotemporal dementia (bvFTD), two developing mixed bvFTD and PSP (Richardson\'s syndrome), one developing bvFTD with Parkinsonism, and three remaining as MCI.

The flex point model demonstrated a change in slope in mI/Cr ratios (*P* = .008) and NAA/mI ratios (*P* = .005; Fig [1](#jon12642-fig-0001){ref-type="fig"}). Representative longitudinal spectra from a converter with *MAPT* mutation are shown in Figure [2](#jon12642-fig-0002){ref-type="fig"}. The increase in the presumed glial marker mI/Cr ratio accelerated 1.86 years prior to symptom onset, and continued to increase with the slope of .04 per year after the flex point (CI: .01, .07, *P* = .008). A similar trajectory of decrease in the NAA/mI ratio accelerated 2.09 years prior to symptom onset, and continued to decline with a slope of ‐.30 per year (CI: ‐.50, ‐.10, *P* = .005). No evidence of longitudinal change was observed in NAA/Cr during the follow‐up period (Table [2](#jon12642-tbl-0002){ref-type="table"}).

![The flex point model for ^1^H MRS metabolite ratios. In the *x* axis, 0 indicates the actual age of symptom onset for converters with *MAPT* mutation. The metabolite ratios are in the *y* axis. The black line shows the predicted values calculated from the flex‐point models. NAA/Cr ratios did not have a "flex‐point" during the follow‐up time window (A). The increase of the presumed glial marker mI/Cr accelerated in 1.86 years prior to symptom onset, and continued to increase in time (B). A similar trajectory of decrease was observed the neuronal marker NAA/mI ratio 2.09 years prior to symptom onset (C). NAA = N‐acetylaspartate; Cr = creatine; mI = myo‐inositol.](JON-29-624-g001){#jon12642-fig-0001}

![Voxel location and representative ^1^H magnetic resonance spectra from a converter with *MAPT* mutation. Posterior cingulate voxel is placed on a mid‐sagittal 3‐dimensional T1‐weighted image (left). Example of ^1^H MRS for a converter with *MAPT* mutation at 2 years before symptom onset (A) and 2 year after symptom onset (B). The spectra are scaled to the creatine (Cr) peak as indicated with the dotted red line. During follow‐up, the myoinositol (mI) peak is elevated from 2 years before symptom onset with mI/Cr ratio of .48 (A) to 2 years after symptom onset with mI/Cr ratio of .57 (B). NAA = N‐acetylaspartate.](JON-29-624-g002){#jon12642-fig-0002}

###### 

Annual Change of Metabolite Ratios on Flex Point Models in Converters with *MAPT* Mutations

                                                                       NAA/Cr                                                              mI/Cr                                                               NAA/mI
  ------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------ --------------------------------------------------------------------
  Intercept                              1.66 (1.60, 1.72)[\*\*\*](#jon12642-tbl2-note-0001){ref-type="fn"}   .49 (.46, .53)[\*\*\*](#jon12642-tbl2-note-0001){ref-type="fn"}    3.37 (3.14, 3.62)[\*\*\*](#jon12642-tbl2-note-0001){ref-type="fn"}
  Overall slope                                                  −.0003 (−.01, .01)                           −.007 (−.01, −.002)[\*](#jon12642-tbl2-note-0001){ref-type="fn"}      .04 (.003, .08)[\*](#jon12642-tbl2-note-0001){ref-type="fn"}
  Slope modifier after the flex point                           −.02 (−0.04, 0.006)                             .02 (.006, .03)[\*](#jon12642-tbl2-note-0001){ref-type="fn"}       −.10 (−.18, −.02)[\*](#jon12642-tbl2-note-0001){ref-type="fn"}
  Flex point dummy variable                                       −.03 (−.08, .03)                             .04 (.01, .07)[\*\*](#jon12642-tbl2-note-0001){ref-type="fn"}      −.30 (−.50, −.10)[\*\*](#jon12642-tbl2-note-0001){ref-type="fn"}

This flex point was estimated in the models using a dummy variable to shift the estimated line with the second slope up or down, thereby moving the flex point left or right. The specific coding in our models estimated a slope over the entire time, and then a modifier to the slope after the flex point. The mixed models used random intercepts to account for within‐subject repeated measures correlations nested in within‐family correlations. ^\*^ *P* \< .05, ^\*\*^ *P* \< .01, ^\*\*\*^ *P* \< .001; CI = confidence interval; Abbreviations: NAA = N‐acetylaspartate; Cr = creatine; mI = myo‐inositol.

John Wiley & Sons, Ltd.

Discussion {#jon12642-sec-0120}
==========

In current study, we report the trajectory of serial ^1^H MRS metabolite ratio changes from the posterior cingulate voxel in *MAPT* mutation carriers who converted from the asymptomatic to symptomatic disease during the longitudinal study. Findings were characterized by a trajectory of increasing mI/Cr and decreasing NAA/mI ratios that begin approximately 2 years prior to symptom onset. Our study extends upon prior cross‐sectional findings of elevated mI/Cr and decreased NAA/mI in asymptomatic *MAPT* mutation carriers.[3](#jon12642-bib-0003){ref-type="ref"}

One of the key findings in our study is the accelerated changes in mI/Cr and NAA/mI that occurred in approximately 2 years prior to symptom onset, suggesting a change in the trajectory of ^1^H MRS metabolite ratios prior to symptom onset. Our findings are consistent with the trajectories reported in a recent longitudinal study of converters with *MAPT* and *GRN* mutations, demonstrating that loss of white matter integrity and grey matter volume were present 2 years before symptom onset.[11](#jon12642-bib-0011){ref-type="ref"} In addition, previous cross‐sectional studies in asymptomatic *MAPT* mutation carriers report presence of ^1^H MRS metabolite ratio abnormalities,[3](#jon12642-bib-0003){ref-type="ref"} grey matter atrophy,[12](#jon12642-bib-0012){ref-type="ref"} loss of white matter integrity,[13](#jon12642-bib-0013){ref-type="ref"} and functional connectivity[14](#jon12642-bib-0014){ref-type="ref"} with range of 5 to 30 years before the estimated age of symptom onset. It should be noted that the cross‐sectional studies estimated the age of onset by the information available from the carriers of the *MAPT* mutation type. Heterogeneity in symptom onset is a common feature across different mutations and within individuals from the same family. On the other hand, in the current study we were able to demonstrate the change in the trajectory of ^1^H MRS metabolite ratios with respect to the actual time of symptom onset during a longitudinal evaluation.

We utilized the flex‐point model by using the multipoint ^1^H MRS datasets to determine when the change in the trajectory of ^1^H MRS metabolites occurred with respect to the time of symptom onset. Flex‐point models have been used to model atrophy rates in preclinical sporadic and familiar Alzheimer\'s disease.[15](#jon12642-bib-0015){ref-type="ref"}, [16](#jon12642-bib-0016){ref-type="ref"} However, no prior studies have used flex‐point models in *MAPT* mutation carriers, making it difficult to compare estimates. Our findings suggest that ^1^H MRS is a useful biomarker for tracking of disease progression starting from the asymptomatic stage.

In agreement with earlier cross‐sectional ^1^H MRS studies in asymptomatic *MAPT* mutation carriers,[3](#jon12642-bib-0003){ref-type="ref"} converters with *MAPT* mutations had increasing mI/Cr ratio in posterior cingulate voxel prior to symptom onset that continued after the age of symptom onset. MI is present in glial cells[17](#jon12642-bib-0017){ref-type="ref"} and thought to be related with glial proliferation and astrocytic and microglial activation.[18](#jon12642-bib-0018){ref-type="ref"}, [19](#jon12642-bib-0019){ref-type="ref"} Elevated mI was reported in both symptomatic and asymptomatic *MAPT* mutation carriers in the posterior cingulate voxel.[3](#jon12642-bib-0003){ref-type="ref"} Elevated mI is also a common feature of MCI and mild AD even with normal NAA/Cr[20](#jon12642-bib-0020){ref-type="ref"}, [21](#jon12642-bib-0021){ref-type="ref"}, [22](#jon12642-bib-0022){ref-type="ref"}, [23](#jon12642-bib-0023){ref-type="ref"} and associated with higher amyloid‐β burden in both cognitively unimpaired individuals[24](#jon12642-bib-0024){ref-type="ref"}, [25](#jon12642-bib-0025){ref-type="ref"} and those with preclinical AD.[26](#jon12642-bib-0026){ref-type="ref"} The posterior cingulate voxel metabolite alterations starting from the asymptomatic stage is characterized by increasing presumed glia marker mI/Cr, followed by decreased NAA/Cr later, may suggest a period of reactive astrocytosis in *MAPT* mutation carriers.

In the current study, decreasing NAA/mI ratios in converters with *MAPT* mutation was mainly driven by increasing mI/Cr ratios, since the slope of the change in neuronal marker NAA/Cr ratios was not different from zero and did not have a "flex‐point" during the follow‐up time window. A similar profile characterized by elevated mI/Cr ratio without NAA/Cr ratio change, are reported not only in asymptomatic *MAPT* mutation carriers, but also in presymptomatic carriers of the amyloid precursor protein (APP) or presenilin 1 (PS1),[27](#jon12642-bib-0027){ref-type="ref"} indicating elevation in mI/Cr precedes a decrease in NAA/Cr in posterior cingulate voxel during the progression of neurodegenerative dementia. The similar pattern of metabolite abnormalities between the *MAPT* mutation carriers and presymptomatic AD with *PS1* and *APP* mutations suggest that the ^1^H MRS changes from posterior cingulate voxel may be early markers of the neurodegenerative pathology in familial neurodegenerative dementias with proteinopathies caused by a variety of different mutations.[3](#jon12642-bib-0003){ref-type="ref"} However, we have recently demonstrated that the neuronal marker NAA/Cr[28](#jon12642-bib-0028){ref-type="ref"}, [29](#jon12642-bib-0029){ref-type="ref"}, [30](#jon12642-bib-0030){ref-type="ref"} from media frontal lobe voxel is decreased in asymptomatic *MAPT* mutation carriers,[31](#jon12642-bib-0031){ref-type="ref"} suggesting ^1^H MRS metabolite alterations may vary by region. Frontal lobes are one of the earliest brain regions involved with neurodegeneration and cortical atrophy in *MAPT* mutation carriers.[32](#jon12642-bib-0032){ref-type="ref"} The limbic pathways are involved as *MAPT* mutation carriers become symptomatic.[33](#jon12642-bib-0033){ref-type="ref"}, [34](#jon12642-bib-0034){ref-type="ref"}

A strength of our study was that the serial ^1^H MRS scans were collected over 10 years, which made the tracking of the disease progression from asymptomatic to symptomatic disease possible. However, the relatively small number of converters was still a limitation. Further assessment in a larger cohort could clarify whether our results are generalizable. Furthermore, data collected from the other brain regions such as the frontal lobes may provide further information on the regional distribution of neurodegenerative pathology, which may be present in the frontal lobes earlier than the posterior cingulate gyrus. In addition, using the absolute quantification of metabolite concentrations rather than the metabolite ratios from ^1^H MRS data and utilizing more advanced acquisition methods to quantify metabolites such as glutamine may provide more information about the mechanisms of metabolite changes associated with *MAPT* mutations in the future.

In conclusion, our data indicate an accelerated change in the ^1^H MRS metabolite ratios in *MAPT* mutation carriers as they transition from asymptomatic to symptomatic disease. Our findings support the utilization of longitudinal ^1^H MRS as a potential biomarker for monitoring the neurodegenerative disease progression in *MAPT* mutation carriers starting from the asymptomatic stage, which may have implications for estimating efficacy in future disease‐modifying trials.
